Insulet Corporation (PODD)

Market Cap	22.67B
Revenue (ttm)	2.36B
Net Income (ttm)	236.10M
Shares Out	70.39M
EPS (ttm)	3.32
PE Ratio	96.93
Forward PE	64.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,789
Open	n/a
Previous Close	320.91
Day's Range	n/a
52-Week Range	226.50 - 353.50
Beta	1.40
Analysts	Strong Buy
Price Target	338.79 (+5.19%)
Earnings Date	Nov 6, 2025

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is cont...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 3,900
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD
• Website: https://www.insulet.com

Financial Performance

In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.

Analyst Summary

According to 19 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price target is $338.79, which is an increase of 5.19% from the latest price.

Price Target

$338.79

(5.19% upside)

Analyst Consensus: Strong Buy